Treatment progress of peripheral T-cell lymphoma
10.3760/cma.j.issn.1009-9921.2018.12.003
- VernacularTitle:外周T细胞淋巴瘤治疗进展
- Author:
Rong HUANG
1
;
Lei FAN
Author Information
1. 210029,南京医科大学第一附属医院 江苏省人民医院血液科
- Keywords:
Lymphoma,T-cell,peripheral;
Treatment
- From:
Journal of Leukemia & Lymphoma
2018;27(12):712-715
- CountryChina
- Language:Chinese
-
Abstract:
Peripheral T-cell lymphoma (PTCL), also known as mature T-cell lymphoma, is a group of malignant proliferative diseases derived from mature T cells. Because natural killer (NK) cells are similar in immunophenotype and function to T cells, NK-cell lymphoma and mature T-cell lymphoma are often classified as one class. The 60th American Society of Hematology (ASH) Annual Meeting has covered various fields about PTCL, especially in terms of treatment. Brentuximab vedotin combined with CHP regimen, histone deacetylase inhibitor combined with HMA regimen, and classic CHOP regimen together with lenalidomide or alemtuzumab provide new options for the treatment of PTCL patients; novel drugs represented by JAK inhibitors, daratumumab, and TP53 inhibitors have also initially demonstrated clinical utility, but large-scale clinical trials are still needed for validation.
